A phase IA, open-label, dose escalation study of patupilone administered intravenously every 3 weeks in adult patients with advanced solid tumors.

Trial Profile

A phase IA, open-label, dose escalation study of patupilone administered intravenously every 3 weeks in adult patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Patupilone (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 28 May 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.
    • 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top